Maternal-Fetal Hemorrhage Rh(D) Immune Globulin Dosage
ورودیهای بالینی بیمار
حداقل ۲۰۰۰ — حداکثر ۶۰۰۰ • واحد: mL
حداقل ۰ — حداکثر ۱۰ • واحد: %
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Standard Dose1–1
- Moderate Hemorrhage2–3
- Large Hemorrhage4–10
- Massive Hemorrhage11–50
The Maternal-Fetal Hemorrhage Rh(D) Immune Globulin Dosage calculator is designed for bedside calculating amount of RhIG (RhoGAM) to be administered to Rh-negative mother following maternal-fetal hemorrhage to prevent hemolytic disease of the fetus and newborn (HDFN) in clinical practice. The resulting score directly guides clinician.
Clinical Guidelines & Evidence
Calculates amount of RhIG (RhoGAM) to be administered to Rh-negative mother following maternal-fetal hemorrhage to prevent hemolytic disease of the fetus and newborn (HDFN). Essential for preventing maternal anti-D antibody formation when Rh-negative mother is exposed to Rh-positive fetal blood.
Clinical Indication
The Maternal-Fetal Hemorrhage Rh(D) Immune Globulin Dosage is indicated for bedside clinical practice to support Calculates amount of RhIG (RhoGAM) to be administered to Rh-negative mother following maternal-fetal hemorrhage to prevent hemolytic disease of the fetus and newborn (HDFN). Essential for preventing maternal anti-D antibody formation when Rh-negative mother is exposed to Rh-positive fetal blood.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: After 12 weeks gestation, full 300 μg dose is recommended.
Number of RhIG vials (300 μg) = (fetal_cell_percentage / 100) × maternal_blood_volume (mL) / 30 mL, rounded to nearest whole number + 1 additional vial for safety margin
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| maternal_blood_volume | float | Yes | Total maternal blood volume in mL. Can be estimated using Nadler's equation based on height and weight, or standard estimates (3,700-4,500 mL for average adult female)(mL) |
| fetal_cell_percentage | float | Yes | Percentage of fetal cells in maternal bloodstream, determined by flow cytometry or Kleihauer-Betke test. Normal baseline is <0.1%, with clinical significance typically >0.3%(%) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 1–1 | Standard Dose | Minimal maternal-fetal hemorrhage |
| 2–3 | Moderate Hemorrhage | Moderate maternal-fetal hemorrhage |
| 4–10 | Large Hemorrhage | Large maternal-fetal hemorrhage |
| 11–50 | Massive Hemorrhage | Massive maternal-fetal hemorrhage |
Evidence-Based References (EBM)
- AABB Technical Manual, 18th edition. American Association of Blood Banks; 2014.
- American College of Obstetricians and Gynecologists. Prevention of Rh D alloimmunization. ACOG Practice Bulletin No. 4. Washington, DC: American College of Obstetricians and Gynecologists; 1999.
- Bowman JM. The prevention of Rh immunization. Transfus Med Rev. 1988;2(3):129-50. doi: 10.1016/s0887-7963(88)70067-9.DOI: 10.1016/s0887-7963(88)70067-9
- Queenan JT, Tomai TP, Ural SH, King JC. Deviation in amniotic fluid optical density at a wavelength of 450 nm in Rh-immunized pregnancies from 14 to 40 weeks' gestation: a proposal for clinical management. Am J Obstet Gynecol. 1993;168(5):1370-6. doi: 10.1016/0002-9378(93)90384-k.DOI: 10.1016/0002-9378(93)90384-k